Medidata Secures a Leader Position in Everest Group’s PEAK Matrix® Assessment for eCOA, Driving the New Patient Experience Forward

Core Insights - Medidata has been recognized as a Leader in Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix® Assessment 2025, supporting over 1 million patients and reducing study build timelines by up to 50% compared to industry standards [1][2][3] Company Overview - Medidata, a brand of Dassault Systèmes, has been a leader in the eCOA market for over a decade, providing foundational solutions for thousands of global studies across various indications [2][4] - The company has celebrated 25 years of technological innovation, supporting over 36,000 trials and 11 million patients, with more than 1 million registered users across approximately 2,300 customers [6] Product Innovations - Medidata eCOA combines advanced technology and operational expertise to launch studies faster than the industry standard, maintaining top data integrity and reducing study build time by up to six weeks compared to the standard of 12 or more weeks [2][4] - Recent partnerships, such as with Cogstate, have enhanced Medidata eCOA with scientific rigor aimed at reducing rater burden and improving signal detection in Central Nervous System (CNS) trials [2] Industry Impact - Medidata's consistent recognition by Everest Group in 2023 and 2024 for Decentralized Clinical Trials highlights its leadership in improving clinical trial operations and accelerating the delivery of life-saving therapies to market [4][6] - The company's commitment to delivering expert advisory and scientific support services contributes to trial success, higher quality data, and superior experiences for patients and sites [2][3]